Humanwell Healthcare (600079) H1 2024 earnings summary

Executive summary

• Revenue for the first half of 2024 reached ¥12.86 billion, up 3.86% year-over-year; net profit attributable to shareholders was ¥1.11 billion, down 16.07% due to lower non-recurring gains compared to last year.

• Core pharmaceutical industrial subsidiaries maintained stable growth, with key products and U.S. generics business expanding; R&D and internationalization advanced, and asset optimization continued.

• Cash flow from operations improved significantly, and the company proposed a cash dividend of ¥1.5 per 10 shares, pending shareholder approval.

Financial highlights

• Operating income: ¥12.86 billion, up 3.86% year-over-year.

• Net profit attributable to shareholders: ¥1.11 billion, down 16.07% year-over-year.

• Net profit excluding non-recurring items: ¥1.09 billion, up 1.68% year-over-year.

• Operating cash flow: ¥846 million, up 119.75% year-over-year.

• Basic EPS: ¥0.68, down 17.07% year-over-year.

Outlook and guidance

• The company will continue to focus on core business, innovation, and international expansion, aiming for sustainable growth amid industry reforms and policy changes.

• Ongoing asset optimization and product pipeline enrichment are expected to enhance competitiveness.